QSimulate announces that it has closed a $2.5M financing round led by quantum technology investment firm 2xN. The other investors in this round are UTokyo IPC and Kyoto iCAP. The proceeds will support QSimulate's rapidly expanding business centered on its quantum physics-based drug-discovery platform, QSP Life. QSP Life currently includes QUELO, QuValent, and QuantumFP, spanning small-molecule lead optimization to covalent inhibitor design, and to ultra-high-throughput molecular fingerprinting.